BioBridgeX vs Cromatic: An Open, Full-Lifecycle Alternative

What is Cromatic, and what is it genuinely good at?

Cromatic is a San Francisco Bay Area startup, founded in 2022 by CEO Dr. Ann Lin (a Stanford genetics PhD and scientific cofounder of Meliora Therapeutics) and CTO Anne Chen (previously a software engineer at Meta). It raised a $5.3 million oversubscribed seed round, announced in November 2023 and led by AgFunder and LifeX Ventures, with participation from investors including Lux Capital and FJ Labs. At the time of that announcement it reported roughly 50 biotech clients, 100+ vetted CROs, and more than $15 million in R&D budgets under management.

The buyer product works in three steps, per Cromatic's own site. You upload your project requirements. Its Sourcerer AI tool analyzes them and returns a curated shortlist of CROs and CDMOs. Then, in Cromatic's words, its white-glove team takes over to connect you with vendors, negotiate terms, and finalize the partnership. Sourcerer, launched in June 2024, can parse a multi-page RFP into distilled objectives and criteria before matching, and there is a free tier for basic single-service searches. The buyer page claims a curated database of 4,500+ CROs and CDMOs across 500+ R&D services, savings of up to 30% per project, and SOC 2 Type II, GDPR, and HIPAA compliance.

Credit where due: the RFP-parsing idea saves real time compared with reading capability decks one by one, and the negotiation support is a genuine draw for a six-person biotech with no procurement function. The founding team's science-plus-software pedigree and the investor list are real strengths.

Cromatic in 2026: Big Brain and the shift toward RevOps

Visit cromatic.bio today and the homepage no longer leads with CRO sourcing. As of August 2026 it titles itself an AI-native RevOps platform for life science business development, built around a product called Big Brain. Big Brain builds lead lists from industry-specific signals (funding rounds, clinical pipeline changes, partnerships) tracked across more than 20 databases, offers access to what Cromatic describes as hundreds of thousands of verified decision-maker emails, drafts outreach, and syncs to your CRM. Its customers are the sell side: CRO, CDMO, and vendor commercial teams prospecting biotech buyers.

The buyer-facing marketplace still exists, but it now lives on a secondary page (cromatic.bio/biotech) under the tagline life science outsourcing, the modern way. The most recent item on Cromatic's own news page is the June 2024 Sourcerer launch, and the current homepage's calls to action route to a 30-minute demo booking.

None of this is a criticism. Broadening into revenue tooling for vendors is a rational move for a venture-backed company. But if you are a biotech buyer evaluating a sourcing platform for the next three years, it is fair to ask which product carries the roadmap, and to verify the answer on their site yourself, because the split focus is visible in public.

Why do biotech buyers look for a Cromatic alternative?

The recurring themes are visibility, pricing, and the hands-on model. Cromatic's vendor database is not browsable on the open web: the claimed 4,500+ CROs and CDMOs sit behind sign-up, and the site's calls to action route to a demo booking or account creation. No pricing is published anywhere on the site either. We checked in August 2026 and found no pricing page and no rates anywhere on the site. The most recent public description of the commercial model is press coverage from November 2023, which reported that biotechs paid an annual subscription plus transaction referral fees while CROs paid referral fees only. Whether that still holds is not published.

The white-glove model itself divides people. Some founders love handing introductions and negotiations to someone else. Others want to hold the vendor relationship directly from the first call, especially when the study is pivotal and the vendor relationship will outlive the platform. Cromatic's own June 2024 press materials also note that its vendor profiles are built with AI tools that gather data from the internet, supported by its internal team and by CRO-provided information, so a shortlist can include providers the platform has profiled rather than onboarded.

We looked for a dedicated G2 review profile for Cromatic in August 2026 and did not find one, so independent review coverage is thin. That is common for early-stage platforms, but it does mean more of your diligence rests on what you can verify yourself.

• You want to browse the supplier pool before creating an account or booking a demo.
• You want published pricing you can model, not terms disclosed during a sales process.
• You want to negotiate and contract with your CRO directly rather than through an intermediary team.
• You want a platform whose sole product is the buyer-supplier marketplace.
• You are sourcing across the full lifecycle, including CMC and manufacturing, not just an R&D study.

What is BioBridgeX and how does it work?

BioBridgeX (BioBridgeX Ltd, London) is a neutral CRO + CDMO marketplace for outsourced drug development. It runs no labs of its own, so it has no in-house capacity to fill and no reason to steer your study toward a preferred site. Its job is to qualify suppliers, match you to the right ones, and let you compare quotes side by side.

The supplier pool is public. More than 260 CRO and CDMO profiles are listed in the open directory, so you can see who is on the platform before you register. Buyers use the platform free, with no subscription. When you post a project, you receive quotes from matched suppliers, compare them in one place, and then contract and pay your chosen supplier directly. BioBridgeX is not a party to that agreement.

Suppliers pay one fee: a flat 2% success fee, owed only when they are awarded the work and the buyer has paid them. There is no listing charge, no subscription tier, and no percentage that changes per request. Coverage runs across the whole lifecycle in one place: discovery, preclinical, IND-enabling, clinical, and CMC/manufacturing. Ready to test it? Register free and compare quotes on your next study.

How does Cromatic pricing compare with BioBridgeX?

BioBridgeX publishes its model in one line: free for buyers, and suppliers pay a flat 2% success fee after the buyer pays them. The rate is identical on a $30k bioanalysis package and a $2M GLP toxicology program, so a supplier can price it into a quote and a buyer knows exactly what economics sit behind the platform.

Cromatic's current pricing is not published. We checked the site in August 2026 and found no pricing page at all: no rates for buyers or vendors anywhere, and no pricing link in the navigation or footer. The best public information is dated: November 2023 press coverage described buyer-side annual subscriptions plus transaction referral fees, with CROs paying referral fees only, and the June 2024 Sourcerer launch described a free basic-search tier plus monthly or annual SaaS plans with no figures disclosed. Big Brain pricing is likewise demo-gated.

Unpublished pricing is not unusual for a managed-service model, and it may well be negotiable in your favor. But it does mean you cannot compare total sourcing cost across platforms from public information alone. If predictable economics matter to your budget model, that difference is structural, not cosmetic.

Vendor discovery: open directory versus gated database

Cromatic claims one of the larger curated databases in the space: 4,500+ CROs and CDMOs spanning 500+ services, per its buyer page. Per its own press materials, those profiles are assembled with AI tools that gather data from the public internet, plus its internal team and information CROs provide directly. That approach buys breadth quickly. It also means database membership is not the same thing as an onboarded, quoting supplier, which is a distinction worth probing on any platform, BioBridgeX included.

BioBridgeX takes the opposite stance on visibility. The directory is public and smaller, at 260+ profiles, and every listed supplier is a real profile you can read before you ever submit a request. You can sanity-check modality coverage, certifications, and service scope in the open, then decide whether to post a project at all.

For a founder, the practical test is simple. Before committing time to either platform, can you see whether three credible providers exist for your specific need, say a 28-day repeat-dose GLP tox study in two species, or sterile fill-finish capacity for a Phase 1 batch? On BioBridgeX that check takes five minutes in the directory. On Cromatic it happens after sign-up or inside a demo.

Lifecycle coverage: where each platform plays

Cromatic positions its marketplace around outsourced R&D: matching sponsors to CROs and CDMOs for research services, with Sourcerer handling the RFP-to-shortlist step. Its claimed 500+ services suggest wide coverage, though the catalog itself is not published for outside review.

BioBridgeX is deliberately organized around the full development arc, so one platform and one process carry you from early biology to commercial supply. In practice that means sourcing discovery and medicinal chemistry, the IND-enabling package (repeat-dose GLP toxicology, the safety pharmacology core battery, genotox, toxicokinetics), clinical-stage services, and then CMC work such as process development and fill-finish manufacturing, without switching platforms when your program graduates from preclinical to manufacturing.

That continuity matters more than it sounds. Teams that source their tox package on one platform, their drug substance on a second, and their fill-finish slot through a banker's introduction end up managing three parallel processes with three sets of terms. A single front door keeps the quote history, the supplier relationships, and the paper trail in one place.

Who is each platform best for?

Cromatic fits early-stage teams that want a hands-off experience: describe the project, receive a shortlist, and let a managed team run introductions and negotiations. If you have no procurement muscle and genuinely prefer delegation, that service layer has real value, and the free Sourcerer tier is a low-risk way to try the matching. Its Big Brain product serves a different audience entirely: CRO and CDMO commercial teams that want AI-driven prospecting and outreach.

BioBridgeX fits biotech founders and program leads who want to see the supplier pool up front, run a structured quote comparison, and hold the contract and the payment relationship themselves. It also fits suppliers who want a publicly discoverable profile and a flat, predictable fee instead of opaque or variable economics. Because buyers contract and pay suppliers directly, the marketplace never sits inside your legal or financial chain.

The honest summary: choose Cromatic if you are buying a managed sourcing service and are comfortable with unpublished terms. Choose BioBridgeX if you are buying transparency: open profiles, published economics, direct contracting, and coverage that extends through CMC. Browse the directory, then register and compare quotes when you have a live project.

Diligence: what to check before you award any study

No marketplace, Cromatic or BioBridgeX, replaces your own diligence. A platform compresses the search from weeks to days, but the decisions that de-risk a program are still yours, and they are the same regardless of where you found the supplier.

Modality fit comes first: a site with deep small-molecule tox experience may be wrong for an AAV gene therapy or a CAR-T program. GLP status is next for anything pivotal, since 21 CFR Part 58 governs studies supporting an IND, and repeating a non-GLP study costs far more than running it correctly once. Then pressure-test capacity and timelines (most IND-enabling programs run 6 to 18 months to a filing-ready package), drug-substance readiness, and how change orders get priced when a study slips.

Finally, force the quotes into one structure before you compare them. Scope, species, group sizes, bioanalysis, reporting, and pass-through costs hide in different line items at different CROs. A standardized RFP going out and a comparison grid coming back turn five incompatible PDFs into a decision you can defend to your board.

• Modality match: small molecule, biologic, ADC, oligonucleotide, cell or gene therapy.
• GLP vs non-GLP, and whether the study is pivotal for your IND.
• Regulatory alignment with FDA, EMA, and ICH expectations (plus OECD GLP for ex-US sites).
• Realistic timelines and true slot availability, not just quoted start dates.
• Drug-substance readiness: enough material, certificates of analysis, stability data.
• Contract terms, IP and data ownership, and the change-order mechanism.